These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25313177)

  • 1. New meets old: a case study and review of novel therapeutics for the treatment of CLL in older patients.
    Gupta NK; Andreadis C
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1371-5. PubMed ID: 25313177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
    James DF; Werner L; Brown JR; Wierda WG; Barrientos JC; Castro JE; Greaves A; Johnson AJ; Rassenti LZ; Rai KR; Neuberg D; Kipps TJ
    J Clin Oncol; 2014 Jul; 32(19):2067-73. PubMed ID: 24868031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide and chronic lymphocytic leukemia.
    González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
    Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
    Bazargan A; Tam CS
    Leuk Lymphoma; 2010 Jan; 51(1):3-4. PubMed ID: 20001866
    [No Abstract]   [Full Text] [Related]  

  • 6. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
    Chavez JC; Piris-Villaespesa M; Dalia S; Powers J; Turba E; Nodzon L; Komrokji R; Sokol L; Locke FL; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Res; 2016 Aug; 47():78-83. PubMed ID: 27285853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy-free treatment of chronic lymphocytic leukemia?].
    Wendtner CM
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2104-6. PubMed ID: 24085367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
    Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
    Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
    Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of lenalidomide in chronic lymphocytic leukemia].
    Lei W; Zhou KS; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    Maurer C; Pflug N; Bahlo J; Kluth S; Rhein C; Cramer P; Gross-Ophoff C; Langerbeins P; Fink AM; Eichhorst B; Kreuzer KA; Fischer N; Tausch E; Stilgenbauer S; Böttcher S; Döhner H; Kneba M; Dreyling M; Binder M; Hallek M; Wendtner CM; Bergmann M; Fischer K;
    Eur J Haematol; 2016 Sep; 97(3):253-60. PubMed ID: 26643449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in CLL: what is the optimal dose?
    Wendtner CM
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):220-4. PubMed ID: 21475128
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.
    Gerrie AS; Toze CL; Ramadan KM; Li CH; Sutherland J; Yee A; Connors JM
    Leuk Lymphoma; 2012 Jan; 53(1):77-82. PubMed ID: 21756026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Cvetković RS; Perry CM
    BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.